Psychiatry Research: Neuroimaging, 55:249-250
Elsevier

Reviewers for 1994

We wish to acknowledge the important assistance we have received from many scientists who, along with the Editorial Board, have evaluated manuscripts submitted for publication during 1994. All outside reviewers are listed in the December issue of *Psychiatry Research* (Volume 54, Number 3, 1994).

Author Index for 1994

Barocka, A., 55:101
Becker, G., 55:75
Becker, T., 55:75
Berman, K.F., 55:51
Bernardo, M., 55:131
Bidaut, L., 55:237
Biver, F., 55:237
Bogdahn, U., 55:75
Boyko, O.B., 55:167
Byrum, C.E., 55:167
Catafau, A.M., 55:131
Charles, H.C., 55:167
Chauchat, J.-H., 55:65
Chittilla, V., 55:167
Cohen, D.J., 55:85, 55:205
Cook, I.A., 55:141
Costa, D.C., 55:193
Cummings, J.L., 55:141
d'Amato, T., 55:65
Daléry, J., 55:65
De la Fuente, J.M., 55:237
Dierks, T., 55:153
Duncan, J.S., 55:85
Dunkin, J.J., 55:141
Dupont, R.M., 55:121
Early, B., 55:167
Easton, P., 55:13
Ebert, D., 55:101
Ell, P.J., 55:193
Feistel, H., 55:101
Franzek, E., 55:153
Fujimoto, T., 55:1
Fukuzako, H., 55:1
Fukuzako, T., 55:1
George, M.S., 55:193
Goldberg, T.E., 55:51
Goldman, S., 55:237
González-Monclús, E., 55:131
Gore, J.C., 55:205
Halpern, S., 55:121
Hamakawa, H., 55:41
Hardin, M.T., 55:85
Harris, M.J., 55:121
Hirakawa, K., 55:1
Hoffer, P.B., 55:181
Hokazono, Y., 55:1
Holzmann, T., 55:111
Hör, G., 55:111
Inubushi, T., 55:41, 55:223
Jeste, D.V., 55:121
John, E.R., 55:13
Kaschka, W., 55:101
Kato, T., 55:41, 55:223
Kosten, T.R., 55:181
Krishnan, K.R.R., 55:167
Krystal, J.H., 55:181
Lachenbruch, P.A., 55:141
Lamoureaux, G., 55:121
Leckman, J.F., 55:85, 55:205
Lehr, P.P., 55:121
Leuchter, A.F., 55:141
Lomeña, F., 55:131
Lotstra, F., 55:237
Lufkin, R.B., 55:141
Luxen, A., 55:237
MacFall, J.R., 55:167
Marie-Cardine, M., 55:65
Martin, J.-P., 55:65
Matsumoto, K., 55:1
Maul, F.-D., 55:111
Maurer, K., 55:153
McMahon, T.J., 55:181
Mena, I., 55:141
Mendlewicz, J., 55:237
Migneco, O., 55:141
Murashita, J., 55:41, 55:223
Newton, T.F., 55:141
O'Connor, P.G., 55:181
Parashos, I., 55:167
Parellada, E., 55:131

Peterson, B.S., 55:85, 55:205
Pflug, B., 55:111
Pilowsky, L., 55:193
Prichep, L. S., 55:13
Riddle, M.A., 55:85, 55:205
Robertson, M.M., 55:193
Rochet, T., 55:65
Rosen, M.I., 55:181
Schreiner, M., 55:111
Setoain, J., 55:131
Shioiri, T., 55:41, 55:223
Stanus, E., 55:237
Stöber, G., 55:153
Strik, W.K., 55:153
Struck, M., 55:75
Sullivan, M., 55:181
Takahashi, S., 55:41, 55:223
Takeuchi, K., 55:1
Takigawa, M., 55:1
Thomas, H.M., 55:181
Torrey, E.F., 55:51
Trimble, M.R., 55:193
Ueyama, K., 55:1
Upchurch, L., 55:167
van Dyck, C.H., 55:181
Verhoeff, N.P.L.G., 55:193
Volk, S., 55:111
Wallace, E.A., 55:181
Walter, D.O., 55:141
Weinberger, D.R., 55:51
Weppner, M., 55:111
Wetzles, R., 55:85
Woods, S.W., 55:181

Subject Index for 1994

Affective disorder
bipolar subtype, event related potential, 55:13
bipolar subtype, phosphorus-31 magnetic resonance spectroscopy, 55:41
bipolar subtype, topographic brain mapping, 55:13
bipolar subtype, ventricle-brain ratio, 55:41
brainstem, ultrasound, 55:75
cingulate gyrus, melancholia, 55:101
cingulate gyrus, single photon emission computed tomography, 55:101
cingulate gyrus, sleep deprivation, 55:101
dorsal raphe, ultrasound, 55:75
event related potential, bipolar subtype, 55:13
event related potential, topographic brain mapping, 55:13
frontal lobe, melancholia, 55:101
frontal lobe, single photon emission computed tomography, 55:101
frontal lobe, sleep deprivation, 55:101
hippocampus, single photon emission computed tomography, 55:101
hippocampus, sleep deprivation, 55:101
magnetic resonance spectroscopy, bipolar subtype, 55:41
magnetic resonance spectroscopy, phosphorus-31, 55:41
melancholia, cingulate gyrus, 55:101
melancholia, frontal lobe, 55:101
melancholia, single photon emission computed tomography, 55:101
melancholia, sleep deprivation, 55:101
phosphorus-31 magnetic resonance spectroscopy, bipolar subtype, 55:41
single photon emission computed tomography, cingulate gyrus, 55:101
single photon emission computed tomography, frontal lobe, 55:101
single photon emission computed tomography, hippocampus, 55:101
single photon emission computed tomography, melancholia, 55:101
single photon emission computed tomography, sleep deprivation, 55:101
sleep deprivation, cingulate gyrus, 55:101
sleep deprivation, frontal lobe, 55:101
sleep deprivation, hippocampus, 55:101
sleep deprivation, melancholia, 55:101
sleep deprivation, single photon emission computed tomography, 55:101
topographic brain mapping, bipolar subtype, 55:13
topographic brain mapping, event related potential, 55:13
ultrasound, brainstem, 55:75
ultrasound, dorsal raphe, 55:75
ventricle-brain ratio, bipolar subtype, 55:41
ventricle-brain ratio, magnetic resonance imaging, 55:41
Aging
frontal lobe, schizophrenia, 55:121
frontal lobe, single photon emission computed tomography, 55:121
Aging, continued
schizophrenia, frontal lobe, 55:121
schizophrenia, single photon emission computed tomography, 55:121
schizophrenia, temporal lobe, 55:121
single photon emission computed tomography, frontal lobe, 55:121
single photon emission computed tomography, schizophrenia, 55:121
single photon emission computed tomography, temporal lobe, 55:121
temporal lobe, schizophrenia, 55:121
temporal lobe, single photon emission computed tomography, 55:121
Alzheimer's disease
electroencephalography, 55:141
regional cerebral blood flow, 55:141
single photon emission computed tomography, 55:141
Amygdala
laterality, magnetic resonance imaging, T2 relaxation, 55:205
laterality, Tourette's syndrome, 55:205
magnetic resonance imaging, laterality, 55:205
magnetic resonance imaging, T2 relaxation, 55:205
magnetic resonance imaging, Tourette's syndrome, 55:205
Tourette's syndrome, laterality, 55:205
Tourette's syndrome, magnetic resonance imaging, 55:205
Tourette's syndrome, T2 relaxation, 55:205
Basal ganglia
dopamine receptors, iodobenzamide, 55:111, 55:193
dopamine receptors, motor tics, 55:193
dopamine receptors, neuroleptic response, 55:111
dopamine receptors, schizophrenia, 55:111
dopamine receptors, single photon emission computed tomography, 55:111, 55:193
dopamine receptors, Tourette's syndrome, 55:193
iodobenzamide, dopamine receptors, 55:111, 55:193
iodobenzamide, motor tics, 55:193
iodobenzamide, neuroleptic response, 55:111
iodobenzamide, schizophrenia, 55:111
iodobenzamide, single photon emission computed tomography, 55:111, 55:193
iodobenzamide, Tourette's syndrome, 55:193
laterality, magnetic resonance imaging, 55:85
laterality, motor tics, 55:85
laterality, Tourette's syndrome, 55:85
magnetic resonance imaging, laterality, 55:85
magnetic resonance imaging, motor tics, 55:85
magnetic resonance imaging, stereology, 55:167
magnetic resonance imaging, Tourette's syndrome, 55:85
magnetic resonance imaging, volume measurement accuracy, 55:167
motor tics, laterality, 55:85
motor tics, Tourette's syndrome, 55:85, 55:193

Basal ganglia continued
neuroleptic response, dopamine receptors, 55:111
neuroleptic response, schizophrenia, 55:111
neuroleptic response, single photon emission computed tomography, 55:111
schizophrenia, dopamine receptors, 55:111
schizophrenia, iodobenzamide, 55:111
schizophrenia, neuroleptic response, 55:111
schizophrenia, single photon emission computed tomography, 55:111
single photon emission computed tomography, dopamine receptors, 55:111, 55:193
single photon emission computed tomography, iodobenzamide, 55:111, 55:193
single photon emission computed tomography, neuroleptic response, 55:111
single photon emission computed tomography, schizophrenia, 55:111
single photon emission computed tomography, Tourette's syndrome, 55:193
stereology, magnetic resonance imaging, 55:167
stereology, volume measurement accuracy, 55:167
Tourette's syndrome, dopamine receptors, 55:193
Tourette's syndrome, iodobenzamide, 55:193
Tourette's syndrome, laterality, 55:85
Tourette's syndrome, magnetic resonance imaging, 55:85
Tourette's syndrome, single photon emission computed tomography, 55:193
volume measurement accuracy, magnetic resonance imaging, 55:167
volume measurement accuracy, stereology, 55:167
Borderline personality disorder
epilepsy, temporal lobe, 55:237
positron emission tomography, temporal lobe, 55:237
temporal lobe, positron emission tomography, 55:237
Buprenorphine
cingulate gyrus, naltrexone, 55:181
cingulate gyrus, regional cerebral blood flow, 55:181
cingulate gyrus, single photon emission computed tomography, 55:181
cingulate gyrus, substance dependence, 55:181
naltrexone, cingulate gyrus, 55:181
naltrexone, regional cerebral blood flow, 55:181
naltrexone, single photon emission computed tomography, 55:181
naltrexone, substance dependence, 55:181
regional cerebral blood flow, cingulate gyrus, 55:181
regional cerebral blood flow, naltrexone, 55:181
regional cerebral blood flow, substance dependence, 55:181
single photon emission computed tomography, cingulate gyrus, 55:181
single photon emission computed tomography, naltrexone, 55:181
single photon emission computed tomography, substance dependence, 55:181
Buprenorphine continued
substance dependence, cingulate gyrus, 55:181
substance dependence, naltrexone, 55:181
substance dependence, regional cerebral blood flow, 55:181
substance dependence, single photon emission computed tomography, 55:181
Cerebral blood flow
Alzheimer's disease, electroencephalography, 55:141
Alzheimer's disease, single photon emission computed tomography, 55:141
buprenorphine, cingulate gyrus, 55:55:181
buprenorphine, single photon emission computed tomography, 55:181
buprenorphine, substance dependence, 55:181
cingulate gyrus, buprenorphine, 55:181
cingulate gyrus, naltrexone, 55:181
cingulate gyrus, single photon emission computed tomography, 55:181
cingulate gyrus, substance dependence, 55:181
electroencephalography, Alzheimer's disease, 55:141
electroencephalography, multi-infarct dementia, 55:141
electroencephalography, single photon emission computed tomography, 55:141
frontal lobe, genetics, 55:51
frontal lobe, neuropsychology, 55:51
frontal lobe, schizophrenia, 55:51
frontal lobe, twins, 55:51
frontal lobe, Wisconsin Card Sort Test, 55:51
genetics, frontal lobe, 55:51
genetics, hippocampus, 55:51
genetics, neuropsychology, 55:51
genetics, schizophrenia, 55:51
genetics, twins, 55:51
genetics, Wisconsin Card Sort Test, 55:51
hippocampus, genetics, 55:51
hippocampus, neuropsychology, 55:51
hippocampus, schizophrenia, 55:51
hippocampus, twins, 55:51
memory, schizophrenia, 55:51
multi-infarct dementia, electroencephalography, 55:141
multi-infarct dementia, single photon emission computed tomography, 55:141
naltrexone, cingulate gyrus, 55:181
naltrexone, single photon emission computed tomography, 55:181
naltrexone, substance dependence, 55:181
neuropsychology, frontal lobe, 55:51
neuropsychology, genetics, 55:51
neuropsychology, hippocampus, 55:51
neuropsychology, schizophrenia, 55:51
neuropsychology, twins, 55:51
neuropsychology, Wisconsin Card Sort Test, 55:51
schizophrenia, frontal lobe, 55:51
schizophrenia, genetics, 55:51
schizophrenia, hippocampus, 55:51
schizophrenia, memory, 55:51
schizophrenia, neuropsychology, 55:51

Cerebral blood flow continued
schizophrenia, twins, 55:51
schizophrenia, Wisconsin Card Sort Test, 55:51
single photon emission computed tomography, Alzheimer's disease, 55:141
single photon emission computed tomography, buprenorphine, 55:181
single photon emission computed tomography, cingulate gyrus, 55:181
single photon emission computed tomography, electroencephalography, 55:141
single photon emission computed tomography, multi-infarct dementia, 55:141
single photon emission computed tomography, naltrexone, 55:181
single photon emission computed tomography, substance dependence, 55:181
substance dependence, buprenorphine, 55:181
substance dependence, cingulate gyrus, 55:181
substance dependence, naltrexone, 55:181
substance dependence, single photon emission computed tomography, 55:181
twins, frontal lobe, 55:51
twins, genetics, 55:51
twins, hippocampus, 55:51
twins, neuropsychology, 55:51
twins, schizophrenia, 55:51
twins, Wisconsin Card Sort Test, 55:51
Wisconsin Card Sort Test, frontal lobe, 55:51
Wisconsin Card Sort Test, genetics, 55:51
Wisconsin Card Sort Test, schizophrenia, 55:51
Wisconsin Card Sort Test, twins, 55:51
Cingulate gyrus
affective disorder, frontal lobe, 55:101
affective disorder, melancholia, 55:101
affective disorder, single photon emission computed tomography, 55:101
affective disorder, sleep deprivation, 55:101
buprenorphine, naltrexone, 55:181
buprenorphine, regional cerebral blood flow, 55:181
buprenorphine, single photon emission computed tomography, 55:181
buprenorphine, substance dependence, 55:181
frontal lobe, affective disorder, 55:101
frontal lobe, melancholia, 55:101
frontal lobe, single photon emission computed tomography, 55:101
frontal lobe, sleep deprivation, 55:101
melancholia, frontal lobe, 55:101
melancholia, single photon emission computed tomography, 55:101
melancholia, sleep deprivation, 55:101
naltrexone, buprenorphine, 55:181
naltrexone, regional cerebral blood flow, 55:181
naltrexone, single photon emission computed tomography, 55:181
naltrexone, substance dependence, 55:181
regional cerebral blood flow, buprenorphine, 55:181
Cingulate gyrus continued
regional cerebral blood flow, naltrexone, 55:181
regional cerebral blood flow, substance dependence, 55:181
single photon emission computed tomography, affective disorder, 55:101
single photon emission computed tomography, buprenorphine, 55:181
single photon emission computed tomography, frontal lobe, 55:101
single photon emission computed tomography, melancholia, 55:101
single photon emission computed tomography, naltrexone, 55:181
single photon emission computed tomography, sleep deprivation, 55:101
single photon emission computed tomography, substance dependence, 55:181
sleep deprivation, affective disorder, 55:101
sleep deprivation, frontal lobe, 55:101
sleep deprivation, melancholia, 55:101
sleep deprivation, single photon emission computed tomography, 55:101
substance dependence, buprenorphine, 55:181
substance dependence, naltrexone, 55:181
substance dependence, regional cerebral blood flow, 55:181
substance dependence, single photon emission computed tomography, 55:181
Circannual rhythms
computed tomography, schizophrenia, 55:65
computed tomography, season of birth, 55:65
computed tomography, ventricle-brain ratio, 55:65
schizophrenia, computed tomography, 55:65
schizophrenia, season of birth, 55:65
schizophrenia, ventricle-brain ratio, 55:65
season of birth, computed tomography, 55:65
season of birth, schizophrenia, 55:65
season of birth, ventricle-brain ratio, 55:65
ventricle-brain ratio, schizophrenia, 55:65
ventricle-brain ratio, season of birth, 55:65
Computed tomography
circannual rhythm, schizophrenia, 55:65
circannual rhythm, ventricle-brain ratio, 55:65
schizophrenia, circannual rhythm, 55:65
schizophrenia, season of birth, 55:65
schizophrenia, third ventricle, 55:65
schizophrenia, ventricle-brain ratio, 55:65
season of birth, schizophrenia, 55:65
season of birth, ventricle-brain ratio, 55:65
third ventricle, schizophrenia, 55:65
ventricle-brain ratio, circannual rhythm, 55:65
ventricle-brain ratio, schizophrenia, 55:65
ventricle-brain ratio, season of birth, 55:65
Corpus callosum
basal ganglia, laterality, 55:85
basal ganglia, magnetic resonance imaging, 55:85
basal ganglia, motor tics, 55:85
basal ganglia, Tourette's syndrome, 55:85
laterality, basal ganglia, 55:85

Corpus callosum continued
laterality, magnetic resonance imaging, 55:85
laterality, motor tics, 55:85
laterality, Tourette's syndrome, 55:85
magnetic resonance imaging, basal ganglia, 55:85
magnetic resonance imaging, laterality, 55:85
magnetic resonance imaging, motor tics, 55:85
magnetic resonance imaging, Tourette's syndrome, 55:85
motor tics, basal ganglia, 55:85
motor tics, laterality, 55:85
motor tics, magnetic resonance imaging, 55:85
Tourette's syndrome, basal ganglia, 55:85
Tourette's syndrome, laterality, 55:85
Tourette's syndrome, magnetic resonance imaging, 55:85
Tourette's syndrome, motor tics, 55:85
Dementia. See also Alzheimer's disease, Multi-infarct dementia
electrophysiology, brain mapping, 55:13
event related potentials, topographic mapping, 55:13
topographic mapping, event related potentials, 55:13
Depression. See Affective disorder
Dopamine
basal ganglia, frontal lobe, 55:111
basal ganglia, iodobenzamide, 55:111, 55:193
basal ganglia, motor tics, 55:193
basal ganglia, neuroleptic response, 55:111
basal ganglia, schizophrenia, 55:111
basal ganglia, single photon emission computed tomography, 55:111, 55:193
basal ganglia, Tourette's syndrome, 55:193
frontal lobe, basal ganglia, 55:111
frontal lobe, iodobenzamide, 55:111
frontal lobe, neuroleptic response, 55:111
frontal lobe, schizophrenia, 55:111
frontal lobe, single photon emission computed tomography, 55:111
iodobenzamide, basal ganglia, 55:111, 55:193
iodobenzamide, frontal lobe, 55:111
iodobenzamide, motor tics, 55:193
iodobenzamide, neuroleptic response, 55:111
iodobenzamide, schizophrenia, 55:111
iodobenzamide, single photon emission computed tomography, 55:111, 55:193
iodobenzamide, Tourette's syndrome, 55:193
motor tics, basal ganglia, 55:193
motor tics, iodobenzamide, 55:193
motor tics, single photon emission computed tomography, 55:193
motor tics, Tourette's syndrome, 55:193
neuroleptic response, basal ganglia, 55:111
neuroleptic response, frontal lobe, 55:111
neuroleptic response, schizophrenia, 55:111
neuroleptic response, single photon emission computed tomography, 55:111
schizophrenia, basal ganglia, 55:111
schizophrenia, frontal lobe, 55:111
Dopamine continued
schizophrenia, neuroleptic response, 55:111
schizophrenia, single photon emission computed tomography, 55:111
single photon emission computed tomography, basal ganglia, 55:111, 55:193
single photon emission computed tomography, frontal lobe, 55:111
single photon emission computed tomography, iodobenzamide, 55:111, 55:193
single photon emission computed tomography, motor tics, 55:193
single photon emission computed tomography, neuroleptic response, 55:111
single photon emission computed tomography, schizophrenia, 55:111
single photon emission computed tomography, Tourette's syndrome, 55:193
Tourette's syndrome, basal ganglia, 55:193
Tourette's syndrome, motor tics, 55:193
Tourette's syndrome, single photon emission computed tomography, 55:193
Dorsal raphe
affective disorder, brainstem, 55:75
affective disorder, ultrasound, 55:75
brainstem, affective disorder, 55:75
brainstem, ultrasound, 55:75
ultrasound, affective disorder, 55:75
ultrasound, brainstem, 55:75
Electroencephalography
alpha wave activity, schizophrenia, 55:1
alpha wave activity, third ventricle, 55:1
alpha wave activity, topographic mapping, 55:1
Alzheimer's disease, regional cerebral blood flow, 55:141
Alzheimer's disease, single photon emission computed tomography, 55:141
magnetic resonance imaging, alpha wave activity, 55:1
magnetic resonance imaging, schizophrenia, 55:1
magnetic resonance imaging, slow wave activity, 55:1
magnetic resonance imaging, third ventricle, 55:1
magnetic resonance imaging, topographic mapping, 55:1
multi-infarct dementia, Alzheimer's disease, 55:141
multi-infarct dementia, regional cerebral blood flow, 55:141
multi-infarct dementia, single photon emission computed tomography, 55:141
regional cerebral blood flow, Alzheimer's disease, 55:141
regional cerebral blood flow, multi-infarct dementia, 55:141
schizophrenia, alpha wave activity, 55:1
schizophrenia, magnetic resonance imaging, 55:1
schizophrenia, slow wave activity, 55:1
schizophrenia, third ventricle, 55:1
schizophrenia, topographic mapping, 55:1
single photon emission computed tomography, Alzheimer's disease, 55:141

Electroencephalography continued
single photon emission computed tomography, multi-infarct dementia, 55:141
single photon emission computed tomography, regional cerebral blood flow, 55:141
slow wave activity, alpha wave activity, 55:1
slow wave activity, schizophrenia, 55:1
slow wave activity, third ventricle, 55:1
slow wave activity, topographic mapping, 55:1
third ventricle, alpha wave activity, 55:1
third ventricle, magnetic resonance imaging, 55:1
third ventricle, schizophrenia, 55:1
third ventricle, slow wave activity, 55:1
third ventricle, topographic mapping, 55:1
topographic mapping, alpha wave activity, 55:1
topographic mapping, magnetic resonance imaging, 55:1
topographic mapping, schizophrenia, 55:1
topographic mapping, slow wave activity, 55:1
topographic mapping, third ventricle, 55:1
Epilepsy
borderline personality disorder, positron emission tomography, 55:237
positron emission tomography, borderline personality disorder, 55:237
temporal lobe, positron emission tomography, 55:237
Event related potentials
affective disorder, bipolar subtype, 55:13
affective disorder, topographic mapping, 55:13
bipolar subtype, topographic mapping, 55:13
laterality, P300, 55:153
laterality, schizophrenia, 55:153
laterality, topographic mapping, 55:153
obsessive-compulsive disorder, topographic mapping, 55:13
P300, laterality, 55:153
P300, schizophrenia, 55:153
P300, topographic mapping, 55:153
schizophrenia, laterality, 55:153
schizophrenia, P300, 55:153
schizophrenia, topographic mapping, 55:13, 55:153
topographic mapping, affective disorder, 55:13
topographic mapping, bipolar subtype, 55:13
topographic mapping, dementia, 55:13
topographic mapping, laterality, 55:153
topographic mapping, obsessive-compulsive disorder, 55:13
topographic mapping, P300, 55:153
topographic mapping, schizophrenia, 55:13, 55:153
Frontal lobe
affective disorder, cingulate gyrus, 55:101
affective disorder, melancholia, 55:101
affective disorder, single photon emission computed tomography, 55:101
affective disorder, sleep deprivation, 55:101
aging, schizophrenia, 55:121
aging, single photon emission computed tomography, 55:121
aging, temporal lobe, 55:121
Frontal lobe continued
amygdala, laterality, 55:205
amygdala, magnetic resonance imaging, 55:205
amygdala, T2 relaxation, 55:205
amygdala, Tourette's syndrome, 55:205
basal ganglia, dopamine receptor, 55:111
basal ganglia, iodobenzamide, 55:111
basal ganglia, neuroleptic response, 55:111
basal ganglia, schizophrenia, 55:111
basal ganglia, single photon emission computed tomography, 55:111
cingulate gyrus, affective disorder, 55:101
cingulate gyrus, melancholia, 55:101
cingulate gyrus, single photon emission computed tomography, 55:101
cingulate gyrus, sleep deprivation, 55:101
dopamine receptor, basal ganglia, 55:111
dopamine receptor, iodobenzamide, 55:111
dopamine receptor, neuroleptic response, 55:111
dopamine receptor, schizophrenia, 55:111
dopamine receptor, single photon emission computed tomography, 55:111
genetics, hippocampus, 55:51
genetics, neuropsychology, 55:51
genetics, regional cerebral blood flow, 55:51
genetics, schizophrenia, 55:51
genetics, twins, 55:51
genetics, Wisconsin Card Sort Test, 55:51
hippocampus, genetics, 55:51
hippocampus, neuropsychology, 55:51
hippocampus, regional cerebral blood flow, 55:51
hippocampus, schizophrenia, 55:51
hippocampus, twins, 55:51
hippocampus, Wisconsin Card Sort Test, 55:51
iodobenzamide, basal ganglia, 55:111
iodobenzamide, dopamine receptor, 55:111
iodobenzamide, neuroleptic response, 55:111
iodobenzamide, schizophrenia, 55:111
iodobenzamide, single photon emission computed tomography, 55:111
laterality, amygdala, 55:205
laterality, magnetic resonance imaging, 55:205
laterality, T2 relaxation, 55:205
laterality, Tourette's syndrome, 55:205
magnetic resonance imaging, amygdala, 55:205
magnetic resonance imaging, laterality, 55:205
magnetic resonance imaging, T2 relaxation, 55:205
magnetic resonance imaging, Tourette's syndrome, 55:205
magnetic resonance spectroscopy, negative symptoms, 55:205
magnetic resonance spectroscopy, phosphomonoesters, 55:223
magnetic resonance spectroscopy, phosphorus-31, 55:223
magnetic resonance spectroscopy, schizophrenia, 55:223
melancholia, affective disorder, 55:101
melancholia, cingulate gyrus, 55:101

Frontal lobe continued
melancholia, single photon emission computed tomography, 55:101
melancholia, sleep deprivation, 55:101
negative symptoms, magnetic resonance spectroscopy, 55:223
negative symptoms, phosphomonoesters, 55:223
negative symptoms, schizophrenia, 55:223
neuroleptic response, basal ganglia, 55:111
neuroleptic response, dopamine receptor, 55:111
neuroleptic response, iodobenzamide, 55:111
neuroleptic response, schizophrenia, 55:111
neuroleptic response, single photon emission computed tomography, 55:111
neuropsychology, genetics, 55:51
neuropsychology, hippocampus, 55:51
neuropsychology, regional cerebral blood flow, 55:51
neuropsychology, schizophrenia, 55:51
neuropsychology, twins, 55:51
neuropsychology, Wisconsin Card Sort Test, 55:51
phosphomonoesters, magnetic resonance spectroscopy, 55:223
phosphomonoesters, negative symptoms, 55:223
phosphomonoesters, schizophrenia, 55:223
phosphorus-31, magnetic resonance spectroscopy, 55:223
regional cerebral blood flow, genetics, 55:51
regional cerebral blood flow, hippocampus, 55:51
regional cerebral blood flow, neuropsychology, 55:51
regional cerebral blood flow, schizophrenia, 55:51
regional cerebral blood flow, twins, 55:51
regional cerebral blood flow, Wisconsin Card Sort Test, 55:51
schizophrenia, aging, 55:121
schizophrenia, basal ganglia, 55:111
schizophrenia, dopamine receptor, 55:111
schizophrenia, genetics, 55:51
schizophrenia, hippocampus, 55:51
schizophrenia, iodobenzamide, 55:111
schizophrenia, magnetic resonance spectroscopy, 55:223
schizophrenia, negative symptoms, 55:223
schizophrenia, neuroleptic response, 55:111
schizophrenia, neuropsychology, 55:51
schizophrenia, phosphomonoesters, 55:223
schizophrenia, regional cerebral blood flow, 55:51
schizophrenia, single photon emission computed tomography, 55:111, 55:121, 55:131
schizophrenia, temporal lobe, 55:121
schizophrenia, twins, 55:51
schizophrenia, Wisconsin Card Sort Test, 55:51, 55:131
single photon emission computed tomography, affective disorder, 55:101
single photon emission computed tomography, aging, 55:121
single photon emission computed tomography, basal ganglia, 55:111
Frontal lobe continued
single photon emission computed tomography, cingulate gyrus, 55:101
single photon emission computed tomography, dopamine receptor, 55:111
single photon emission computed tomography, iodobenzamide, 55:111
single photon emission computed tomography, melancholia, 55:101
single photon emission computed tomography, neuroleptic response, 55:111
single photon emission computed tomography, schizophrenia, 55:111, 55:121, 55:131
single photon emission computed tomography, sleep deprivation, 55:101
single photon emission computed tomography, temporal lobe, 55:121
single photon emission computed tomography, Wisconsin Card Sort Test, 55:131
sleep deprivation, affective disorder, 55:101
sleep deprivation, cingulate gyrus, 55:101
sleep deprivation, melancholia, 55:101
sleep deprivation, single photon emission computed tomography, 55:101
T2 relaxation, amygdala, 55:205
T2 relaxation, laterality, 55:205
T2 relaxation, magnetic resonance imaging, 55:205
T2 relaxation, Tourette's syndrome, 55:205
temporal lobe, aging, 55:121
temporal lobe, schizophrenia, 55:121
temporal lobe, single photon emission computed tomography, 55:121
Tourette's syndrome, amygdala, 55:205
Tourette's syndrome, laterality, 55:205
Tourette's syndrome, magnetic resonance imaging, 55:205
Tourette's syndrome, T2 relaxation, 55:205
twins, genetics, 55:51
twins, hippocampus, 55:51
twins, neuropsychology, 55:51
twins, regional cerebral blood flow, 55:51
twins, schizophrenia, 55:51
twins, Wisconsin Card Sort Test, 55:51
Wisconsin Card Sort Test, genetics, 55:51
Wisconsin Card Sort Test, hippocampus, 55:51
Wisconsin Card Sort Test, neuropsychology, 55:51
Wisconsin Card Sort Test, regional cerebral blood flow, 55:51
Wisconsin Card Sort Test, schizophrenia, 55:51, 55:131
Wisconsin Card Sort Test, single photon emission computed tomography, 55:131
Wisconsin Card Sort Test, twins, 55:51
Genetics
frontal lobe, neuropsychology, 55:51
frontal lobe, regional cerebral blood flow, 55:51
frontal lobe, schizophrenia, 55:51
frontal lobe, Wisconsin Card Sort Test, 55:51
hippocampus, neuropsychology, 55:51

Genetics continued
hippocampus, regional cerebral blood flow, 55:51
hippocampus, schizophrenia, 55:51
hippocampus, Wisconsin Card Sort Test, 55:51
neuropsychology, frontal lobe, 55:51
neuropsychology, hippocampus, 55:51
neuropsychology, regional cerebral blood flow, 55:51
neuropsychology, schizophrenia, 55:51
regional cerebral blood flow, frontal lobe, 55:51
regional cerebral blood flow, hippocampus, 55:51
regional cerebral blood flow, neuropsychology, 55:51
regional cerebral blood flow, schizophrenia, 55:51
regional cerebral blood flow, Wisconsin Card Sort Test, 55:51
schizophrenia, frontal lobe, 55:51
schizophrenia, hippocampus, 55:51
schizophrenia, neuropsychology, 55:51
schizophrenia, regional cerebral blood flow, 55:51
schizophrenia, Wisconsin Card Sort Test, 55:51
twins, frontal lobe, 55:51
twins, hippocampus, 55:51
twins, neuropsychology, 55:51
twins, regional cerebral blood flow, 55:51
twins, schizophrenia, 55:51
twins, Wisconsin Card Sort Test, 55:51
Wisconsin Card Sort Test, frontal lobe, 55:51
Wisconsin Card Sort Test, hippocampus, 55:51
Wisconsin Card Sort Test, regional cerebral blood flow, 55:51
Wisconsin Card Sort Test, schizophrenia, 55:51
Hippocampus
affective disorder, single photon emission computed tomography, 55:101
affective disorder, sleep deprivation, 55:101
genetics, neuropsychology, 55:51
genetics, regional cerebral blood flow, 55:51
genetics, schizophrenia, 55:51
neuropsychology, genetics, 55:51
neuropsychology, regional cerebral blood flow, 55:51
neuropsychology, schizophrenia, 55:51
neuropsychology, twins, 55:51
regional cerebral blood flow, genetics, 55:51
regional cerebral blood flow, neuropsychology, 55:51
regional cerebral blood flow, schizophrenia, 55:51
schizophrenia, genetics, 55:51
schizophrenia, neuropsychology, 55:51
schizophrenia, regional cerebral blood flow, 55:51
single photon emission computed tomography, affective disorder, 55:101
single photon emission computed tomography, sleep deprivation, 55:101
sleep deprivation, affective disorder, 55:101
sleep deprivation, single photon emission computed tomography, 55:101
twins, genetics, 55:51
twins, neuropsychology, 55:51
Hippocampus continued
twins, regional cerebral blood flow, 55:51
twins, schizophrenia, 55:51
Iodobenzamide
basal ganglia, dopamine receptor, 55:111, 55:193
basal ganglia, neuroleptic response, 55:111
basal ganglia, schizophrenia, 55:111
basal ganglia, single photon emission computed tomography, 55:111, 55:193
basal ganglia, Tourette's syndrome, 55:193
dopamine receptor, basal ganglia, 55:111, 55:193
dopamine receptor, neuroleptic response, 55:111
dopamine receptor, schizophrenia, 55:111
dopamine receptor, single photon emission computed tomography, 55:111, 55:193
dopamine receptor, Tourette's syndrome, 55:193
frontal lobe, neuroleptic response, 55:111
frontal lobe, schizophrenia, 55:111
frontal lobe, single photon emission computed tomography, 55:111
motor tics, basal ganglia, 55:193
motor tics, dopamine receptor, 55:193
motor tics, single photon emission computed tomography, 55:193
neuroleptic response, basal ganglia, 55:111
neuroleptic response, dopamine receptor, 55:111
neuroleptic response, frontal lobe, 55:111
neuroleptic response, schizophrenia, 55:111
neuroleptic response, single photon emission computed tomography, 55:111
schizophrenia, basal ganglia, 55:111
schizophrenia, dopamine receptor, 55:111
schizophrenia, frontal lobe, 55:111
schizophrenia, neuroleptic response, 55:111
schizophrenia, single photon emission computed tomography, 55:111
single photon emission computed tomography, basal ganglia, 55:111, 55:193
single photon emission computed tomography, dopamine receptor, 55:111, 55:193
single photon emission computed tomography, frontal lobe, 55:111
single photon emission computed tomography, neuroleptic response, 55:111
single photon emission computed tomography, schizophrenia, 55:111
single photon emission computed tomography, Tourette's syndrome, 55:193
Tourette's syndrome, basal ganglia, 55:193
Tourette's syndrome, dopamine receptor, 55:193
Tourette's syndrome, motor tics, 55:193
Tourette's syndrome, single photon emission computed tomography, 55:193
Laterality
amygdala, frontal lobe white matter, 55:205
amygdala, magnetic resonance imaging, 55:205
amygdala, T2 relaxation, 55:205
amygdala, Tourette's syndrome, 55:205
basal ganglia, magnetic resonance imaging, 55:85
basal ganglia, motor tics, 55:85

Laterality continued
basal ganglia, Tourette's syndrome, 55:85
corpus callosum, magnetic resonance imaging, 55:85
corpus callosum, motor tics, 55:85
corpus callosum, Tourette's syndrome, 55:85
event related potential, P300, 55:153
event related potential, schizophrenia, 55:153
event related potential, topographic mapping, 55:153
frontal lobe white matter, amygdala, 55:205
frontal lobe white matter, magnetic resonance imaging, 55:205
frontal lobe white matter, T2 relaxation, 55:205
frontal lobe white matter, Tourette's syndrome, 55:205
magnetic resonance imaging, amygdala, 55:205
magnetic resonance imaging, basal ganglia, 55:85
magnetic resonance imaging, corpus callosum, 55:85
magnetic resonance imaging, frontal lobe white matter, 55:205
magnetic resonance imaging, motor tics, 55:85
magnetic resonance imaging, T2 relaxation, 55:205
magnetic resonance imaging, Tourette's syndrome, 55:85, 55:205
motor tics, basal ganglia, 55:85
motor tics, corpus callosum, 55:85
motor tics, magnetic resonance imaging, 55:85
motor tics, Tourette's syndrome, 55:85
P300, event related potential, 55:153
P300, schizophrenia, 55:153
P300, topographic mapping, 55:153
schizophrenia, event related potential, 55:153
schizophrenia, P300, 55:153
schizophrenia, topographic mapping, 55:153
T2 relaxation, amygdala, 55:205
T2 relaxation, frontal lobe white matter, 55:205
T2 relaxation, magnetic resonance imaging, 55:205
T2 relaxation, Tourette's syndrome, 55:205
topographic mapping, event related potential, 55:153
topographic mapping, P300, 55:153
topographic mapping, schizophrenia, 55:153
Tourette's syndrome, amygdala, 55:205
Tourette's syndrome, basal ganglia, 55:85
Tourette's syndrome, corpus callosum, 55:85
Tourette's syndrome, frontal lobe white matter, 55:205
Tourette's syndrome, magnetic resonance imaging, 55:85, 55:205
Tourette's syndrome, motor tics, 55:85
Tourette's syndrome, T2 relaxation, 55:205
Magnetic resonance imaging
alpha wave activity, electroencephalography, 55:1
alpha wave activity, schizophrenia, 55:1
alpha wave activity, topographic mapping, 55:1
amygdala, frontal lobe white matter, 55:205
amygdala, laterality, 55:205
amygdala, T2 relaxation, 55:205
Magnetic resonance imaging continued
amygdala, Tourette's syndrome, 55:205
basal ganglia, corpus callosum, 55:85
basal ganglia, laterality, 55:85
basal ganglia, motor tics, 55:85
basal ganglia, stereology, 55:167
basal ganglia, Tourette's syndrome, 55:85
basal ganglia, volume measurement accuracy, 55:167
corpus callosum, basal ganglia, 55:85
corpus callosum, laterality, 55:85
corpus callosum, motor tics, 55:85
corpus callosum, Tourette's syndrome, 55:85
electroencephalography, alpha wave activity, 55:1
electroencephalography, schizophrenia, 55:1
electroencephalography, slow wave activity, 55:1
electroencephalography, third ventricle, 55:1
electroencephalography, topographic mapping, 55:1
frontal lobe white matter, amygdala, 55:205
frontal lobe white matter, laterality, 55:205
frontal lobe white matter, T2 relaxation, 55:205
frontal lobe white matter, Tourette's syndrome, 55:205
laterality, amygdala, 55:205
laterality, basal ganglia, 55:85
laterality, corpus callosum, 55:85
laterality, frontal lobe white matter, 55:205
laterality, motor tics, 55:85
laterality, T2 relaxation, 55:205
laterality, Tourette's syndrome, 55:85, 55:205
magnetic resonance spectroscopy, phosphomonoesters, 55:41
motor tics, basal ganglia, 55:85
motor tics, laterality, 55:85
motor tics, Tourette's syndrome, 55:85
phosphomonoesters, magnetic resonance spectroscopy, 55:41
schizophrenia, alpha wave activity, 55:1
schizophrenia, electroencephalography, 55:1
schizophrenia, slow wave activity, 55:1
schizophrenia, third ventricle, 55:1
schizophrenia, topographic mapping, 55:1
slow wave activity, alpha wave activity, 55:1
slow wave activity, electroencephalography, 55:1
slow wave activity, schizophrenia, 55:1
slow wave activity, third ventricle, 55:1
slow wave activity, topographic mapping, 55:1
stereology, basal ganglia, 55:167
stereology, volume measurement accuracy, 55:167
T2 relaxation, amygdala, 55:205
T2 relaxation, frontal lobe white matter, 55:205
T2 relaxation, laterality, 55:205
T2 relaxation, Tourette's syndrome, 55:205
third ventricle, alpha wave activity, 55:1
third ventricle, electroencephalography, 55:1
third ventricle, schizophrenia, 55:1
third ventricle, slow wave activity, 55:1
third ventricle, topographic mapping, 55:1
topographic mapping, alpha wave activity, 55:1
topographic mapping, electroencephalography, 55:1

Magnetic resonance imaging continued
topographic mapping, schizophrenia, 55:1
topographic mapping, slow wave activity, 55:1
topographic mapping, third ventricle, 55:1
Tourette's syndrome, amygdala, 55:205
Tourette's syndrome, basal ganglia, 55:85
Tourette's syndrome, corpus callosum, 55:85
Tourette's syndrome, frontal lobe white matter, 55:205
Tourette's syndrome, laterality, 55:85, 55:205
Tourette's syndrome, motor tics, 55:85
Tourette's syndrome, T2 relaxation, 55:205
volume measurement accuracy, basal ganglia, 55:167
volume measurement accuracy, stereology, 55:167
Magnetic resonance spectroscopy
affective disorder, bipolar subtype, 55:41
affective disorder, ventricle-brain ratio, 55:41
bipolar affective disorder, ventricle-brain ratio, 55:41
frontal lobe, negative symptoms, 55:223
frontal lobe, phosphomonoesters, 55:223
frontal lobe, schizophrenia, 55:223
magnetic resonance imaging, phosphomonoesters, 55:41
negative symptoms, frontal lobe, 55:223
negative symptoms, phosphomonoesters, 55:223
negative symptoms, schizophrenia, 55:223
phosphomonoesters, frontal lobe, 55:223
phosphomonoesters, magnetic resonance imaging, 55:41
phosphomonoesters, negative symptoms, 55:223
phosphomonoesters, schizophrenia, 55:223
phosphorus-31, affective disorder, bipolar subtype, 55:41
phosphorus-31, frontal lobe, 55:223
phosphorus-31, negative symptoms, 55:223
phosphorus-31, schizophrenia, 55:223
phosphorus-31, ventricle-brain ratio, 55:41
schizophrenia, frontal lobe, 55:223
schizophrenia, negative symptoms, 55:223
schizophrenia, phosphomonoesters, 55:223
schizophrenia, phosphorus-31, 55:223
ventricle-brain ratio, affective disorder, bipolar subtype, 55:41
Memory
regional cerebral blood flow, schizophrenia, 55:51
schizophrenia, regional cerebral blood flow, 55:51
Motor tics. See Tourette's syndrome
Multi-infarct dementia
electroencephalography, regional cerebral blood flow, 55:141
electroencephalography, single photon emission computed tomography, 55:141
regional cerebral blood flow, electroencephalography, 55:141
regional cerebral blood flow, single photon emission computed tomography, 55:141
single photon emission computed tomography, electroencephalography, 55:141
Multi-infarct dementia continued
single photon emission computed tomography, regional cerebral blood flow, 55:141
Naltrexone
buprenorphine, cingulate gyrus, 55:181
buprenorphine, regional cerebral blood flow, 55:181
buprenorphine, single photon emission computed tomography, 55:181
buprenorphine, substance dependence, 55:181
cingulate gyrus, buprenorphine, 55:181
cingulate gyrus, regional cerebral blood flow, 55:181
cingulate gyrus, single photon emission computed tomography, 55:181
cingulate gyrus, substance dependence, 55:181
regional cerebral blood flow, buprenorphine, 55:181
regional cerebral blood flow, cingulate gyrus, 55:181
regional cerebral blood flow, substance dependence, 55:181
single photon emission computed tomography, buprenorphine, 55:181
single photon emission computed tomography, cingulate gyrus, 55:181
single photon emission computed tomography, substance dependence, 55:181
substance dependence, buprenorphine, 55:181
substance dependence, cingulate gyrus, 55:181
substance dependence, regional cerebral blood flow, 55:181
substance dependence, single photon emission computed tomography, 55:181
Neuroleptic response
basal ganglia, dopamine receptor, 55:111
basal ganglia, iodobenzamide, 55:111
basal ganglia, schizophrenia, 55:111
basal ganglia, single photon emission computed tomography, 55:111
dopamine receptor, basal ganglia, 55:111
dopamine receptor, iodobenzamide, 55:111
dopamine receptor, schizophrenia, 55:111
dopamine receptor, single photon emission computed tomography, 55:111
frontal lobe, iodobenzamide, 55:111
frontal lobe, schizophrenia, 55:111
frontal lobe, single photon emission computed tomography, 55:111
iodobenzamide, basal ganglia, 55:111
iodobenzamide, dopamine receptor, 55:111
iodobenzamide, frontal lobe, 55:111
iodobenzamide, schizophrenia, 55:111
iodobenzamide, single photon emission computed tomography, 55:111
schizophrenia, basal ganglia, 55:111
schizophrenia, dopamine receptor, 55:111
schizophrenia, frontal lobe, 55:111
schizophrenia, iodobenzamide, 55:111
schizophrenia, single photon emission computed tomography, 55:111

Neuroleptic response continued
single photon emission computed tomography, basal ganglia, 55:111
single photon emission computed tomography, dopamine receptor, 55:111
single photon emission computed tomography, frontal lobe, 55:111
single photon emission computed tomography, iodobenzamide, 55:111
single photon emission computed tomography, schizophrenia, 55:111
Neuropsychology
frontal lobe, regional cerebral blood flow, 55:51
frontal lobe, schizophrenia, 55:51
frontal lobe, twins, 55:51
frontal lobe, Wisconsin Card Sort Test, 55:51
genetics, frontal lobe, 55:51
genetics, hippocampus, 55:51
genetics, regional cerebral blood flow, 55:51
genetics, schizophrenia, 55:51
genetics, Wisconsin Card Sort Test, 55:51
hippocampus, regional cerebral blood flow, 55:51
hippocampus, schizophrenia, 55:51
hippocampus, twins, 55:51
hippocampus, Wisconsin Card Sort Test, 55:51
regional cerebral blood flow, frontal lobe, 55:51
regional cerebral blood flow, genetics, 55:51
regional cerebral blood flow, hippocampus, 55:51
regional cerebral blood flow, schizophrenia, 55:51
regional cerebral blood flow, Wisconsin Card Sort Test, 55:51
schizophrenia, frontal lobe, 55:51
schizophrenia, genetics, 55:51
schizophrenia, hippocampus, 55:51
schizophrenia, regional cerebral blood flow, 55:51
schizophrenia, twins, 55:51
schizophrenia, Wisconsin Card Sort Test, 55:51
twins, frontal lobe, 55:51
twins, hippocampus, 55:51
twins, regional cerebral blood flow, 55:51
twins, schizophrenia, 55:51
twins, Wisconsin Card Sort Test, 55:51
Wisconsin Card Sort Test, frontal lobe, 55:51
Wisconsin Card Sort Test, genetics, 55:51
Wisconsin Card Sort Test, regional cerebral blood flow, 55:51
Wisconsin Card Sort Test, schizophrenia, 55:51
Wisconsin Card Sort Test, twins, 55:51
Obsessive-compulsive disorder
event related potentials, topographic mapping, 55:13
topographic mapping, event related potentials, 55:13
Phosphomonoesters
frontal lobe, magnetic resonance spectroscopy, 55:223
frontal lobe, negative symptoms, 55:223
frontal lobe, phosphorus-31, 55:223
frontal lobe, schizophrenia, 55:223
Phosphomonoesters continued
magnetic resonance imaging, magnetic resonance spectroscropy, 55:41
magnetic resonance spectroscopy, frontal lobe, 55:223
magnetic resonance spectroscopy, negative symptoms, 55:223
magnetic resonance spectroscopy, phosphorus-31, 55:223
magnetic resonance spectroscopy, schizophrenia, 55:223
negative symptoms, frontal lobe, 55:223
negative symptoms, magnetic resonance spectroscopy, 55:223
negative symptoms, schizophrenia, 55:223
phosphorus-31, magnetic resonance spectroscopy, 55:223
schizophrenia, frontal lobe, 55:223
schizophrenia, magnetic resonance spectroscopy, 55:223
schizophrenia, negative symptoms, 55:223
Positron emission tomography
borderline personality disorder, temporal lobe epilepsy, 55:237
Regional cerebral blood flow. See Cerebral blood flow
Schizophrenia
aging, frontal lobe, 55:121
aging, single photon emission computed tomography, 55:121
aging, temporal lobe, 55:121
alpha wave activity, electroencephalography, 55:1
alpha wave activity, topographic mapping, 55:1
basal ganglia, dopamine receptor, 55:111
basal ganglia, iodobenzamide, 55:111
basal ganglia, neuroleptic response, 55:111
basal ganglia, single photon emission computed tomography, 55:111
circannual rhythm, computed tomography, 55:65
circannual rhythm, season of birth, 55:65
circannual rhythm, ventricle-brain ratio, 55:65
computed tomography, circannual rhythm, 55:65
computed tomography, season of birth, 55:65
computed tomography, third ventricle, 55:65
computed tomography, ventricle-brain ratio, 55:65
dopamine receptor, basal ganglia, 55:111
dopamine receptor, frontal lobe, 55:111
dopamine receptor, iodobenzamide, 55:111
dopamine receptor, neuroleptic response, 55:111
dopamine receptor, single photon emission computed tomography, 55:111
electroencephalography, alpha wave activity, 55:1
electroencephalography, slow wave activity, 55:1
electroencephalography, topographic mapping, 55:1
event related potential, laterality, 55:153
event related potential, P300 component, 55:153
event related potential, topographic mapping, 55:13 55:153
frontal lobe, aging, 55:121
frontal lobe, dopamine receptor, 55:111

Schizophrenia continued
frontal lobe, genetics, 55:51
frontal lobe, iodobenzamide, 55:111
frontal lobe, magnetic resonance spectroscopy, 55:223
frontal lobe, negative symptoms, 55:223
frontal lobe, neuroleptic response, 55:111
frontal lobe, neuropsychology, 55:51
frontal lobe, phosphomonoesters, 55:223
frontal lobe, regional cerebral blood flow, 55:51
frontal lobe, single photon emission computed tomography, 55:111, 55:121, 55:131
frontal lobe, temporal lobe, 55:121
frontal lobe, twins, 55:51
frontal lobe, Wisconsin Card Sort Test, 55:51, 55:131
genetics, frontal lobe, 55:51
genetics, hippocampus, 55:51
genetics, neuropsychology, 55:51
genetics, regional cerebral blood flow, 55:51
genetics, twins, 55:51
genetics, Wisconsin Card Sort Test, 55:51
hippocampus, genetics, 55:51
hippocampus, neuropsychology, 55:51
hippocampus, regional cerebral blood flow, 55:51
hippocampus, twins, 55:51
iodobenzamide, basal ganglia, 55:111
iodobenzamide, dopamine receptor, 55:111
iodobenzamide, frontal lobe, 55:111
iodobenzamide, neuroleptic response, 55:111
iodobenzamide, single photon emission computed tomography, 55:111
laterality, event related potential, 55:153
laterality, P300 component, 55:153
laterality, topographic mapping, 55:153
magnetic resonance imaging, third ventricle, 55:1
magnetic resonance spectroscopy, frontal lobe, 55:223
magnetic resonance spectroscopy, negative symptoms, 55:223
magnetic resonance spectroscopy, phosphomonoesters, 55:223
magnetic resonance spectroscopy, phosphorus-31, 55:223
memory, regional cerebral blood flow, 55:51
negative symptoms, frontal lobe, 55:223
negative symptoms, magnetic resonance spectroscopy, 55:223
negative symptoms, phosphomonoesters, 55:223
neuroleptic response, basal ganglia, 55:111
neuroleptic response, dopamine receptor, 55:111
neuroleptic response, frontal lobe, 55:111
neuroleptic response, iodobenzamide, 55:111
neuroleptic response, single photon emission computed tomography, 55:111
neuropsychology, frontal lobe, 55:51
neuropsychology, genetics, 55:51
neuropsychology, hippocampus, 55:51
neuropsychology, regional cerebral blood flow, 55:51

Schizophrenia continued
neuropsychology, twins, 55:51
neuropsychology, Wisconsin Card Sort Test, 55:51
P300 event related potential component, laterality, 55:153
P300 event related potential component, topographic mapping, 55:153
phosphomonoesters, frontal lobe, 55:223
phosphomonoesters, magnetic resonance spectroscopy, 55:223
phosphomonoesters, negative symptoms, 55:223
phosphorus-31, magnetic resonance spectroscopy, 55:223
regional cerebral blood flow, frontal lobe, 55:51
regional cerebral blood flow, genetics, 55:51
regional cerebral blood flow, hippocampus, 55:51
regional cerebral blood flow, memory, 55:51
regional cerebral blood flow, neuropsychology, 55:51
regional cerebral blood flow, twins, 55:51
regional cerebral blood flow, Wisconsin Card Sort Test, 55:51
season of birth, circannual rhythm, 55:65
season of birth, computed tomography, 55:65
season of birth, ventricle-brain ratio, 55:65
single photon emission computed tomography, aging, 55:121
single photon emission computed tomography, basal ganglia, 55:111
single photon emission computed tomography, dopamine receptor, 55:111
single photon emission computed tomography, frontal lobe, 55:111, 55:121, 55:131
single photon emission computed tomography, iodobenzamide, 55:111
single photon emission computed tomography, neuroleptic response, 55:111
single photon emission computed tomography, temporal lobe, 55:121
single photon emission computed tomography, Wisconsin Card Sort Test, 55:131
slow wave activity, electroencephalography, 55:1
slow wave activity, topographic mapping, 55:1
temporal lobe, aging, 55:121
temporal lobe, single photon emission computed tomography, 55:121
third ventricle, computed tomography, 55:65
third ventricle, magnetic resonance imaging, 55:1
topographic mapping, alpha wave activity, 55:1
topographic mapping, electroencephalography, 55:1
topographic mapping, event related potential, 55:13, 55:153
topographic mapping, laterality, 55:153
topographic mapping, P300, 55:153
topographic mapping, slow wave activity, 55:1
twins, frontal lobe, 55:51
twins, hippocampus, 55:51
twins, neuropsychology, 55:51
twins, regional cerebral blood flow, 55:51
twins, Wisconsin Card Sort Test, 55:51

Schizophrenia continued
ventricle-brain ratio, circannual rhythm, 55:65
ventricle-brain ratio, computed tomography, 55:65
ventricle-brain ratio, season of birth, 55:65
Wisconsin Card Sort Test, frontal lobe, 55:51, 55:131
Wisconsin Card Sort Test, genetics, 55:51
Wisconsin Card Sort Test, regional cerebral blood flow, 55:51
Wisconsin Card Sort Test, single photon emission computed tomography, 55:131
Wisconsin Card Sort Test, twins, 55:51
Single photon emission computed tomography
affective disorder, cingulate gyrus, 55:101
affective disorder, frontal lobe, 55:101
affective disorder, hippocampus, 55:101
affective disorder, melancholia, 55:101
affective disorder, sleep deprivation, 55:101
aging, frontal lobe, 55:121
aging, schizophrenia, 55:121
aging, temporal lobe, 55:121
Alzheimer's disease, electroencephalography, 55:141
basal ganglia, dopamine receptor, 55:111, 55:193
basal ganglia, frontal lobe, 55:111
basal ganglia, iodobenzamide, 55:111, 55:193
basal ganglia, motor tics, 55:193
basal ganglia, neuroleptic response, 55:111
basal ganglia, schizophrenia, 55:111
basal ganglia, Tourette's syndrome, 55:193
buprenorphine, cingulate gyrus, 55:181
buprenorphine, naltrexone, 55:181
buprenorphine, regional cerebral blood flow, 55:181
buprenorphine, substance dependence, 55:181
cingulate gyrus, affective disorder, 55:101
cingulate gyrus, buprenorphine, 55:181
cingulate gyrus, frontal lobe, 55:101
cingulate gyrus, melancholia, 55:101
cingulate gyrus, naltrexone, 55:181
cingulate gyrus, sleep deprivation, 55:101
cingulate gyrus, substance dependence, 55:181
dopamine receptor, basal ganglia, 55:111, 55:193
dopamine receptor, frontal lobe, 55:111
dopamine receptor, iodobenzamide, 55:111, 55:193
dopamine receptor, motor tics, 55:193
dopamine receptor, neuroleptic response, 55:111
dopamine receptor, schizophrenia, 55:111
dopamine receptor, Tourette's syndrome, 55:193
electroencephalography, Alzheimer's disease, 55:141
electroencephalography, multi-infarct dementia, 55:141
frontal lobe, affective disorder, 55:101
frontal lobe, aging, 55:121
frontal lobe, basal ganglia, 55:111
frontal lobe, cingulate gyrus, 55:101
frontal lobe, dopamine receptor, 55:111
frontal lobe, iodobenzamide, 55:111
frontal lobe, melancholia, 55:101
frontal lobe, neuroleptic response, 55:111
frontal lobe, schizophrenia, 55:111, 55:121, 55:131
Single photon emission computed tomography continued
frontal lobe, sleep deprivation, 55:101
frontal lobe, temporal lobe, 55:121
frontal lobe, Wisconsin Card Sort Test, 55:131
hippocampus, affective disorder, 55:101
hippocampus, sleep deprivation, 55:101
iodobenzamide, basal ganglia, 55:111, 55:193
iodobenzamide, dopamine receptor, 55:111, 55:193
iodobenzamide, frontal lobe, 55:111
iodobenzamide, motor tics, 55:193
iodobenzamide, neuroleptic response, 55:111
iodobenzamide, schizophrenia, 55:111
iodobenzamide, Tourette's syndrome, 55:193
melancholia, affective disorder, 55:101
melancholia, cingulate gyrus, 55:101
melancholia, frontal lobe, 55:101
melancholia, sleep deprivation, 55:101
motor tics, basal ganglia, 55:193
motor tics, dopamine receptor, 55:193
motor tics, iodobenzamide, 55:193
motor tics, Tourette's syndrome, 55:193
multi-infarct dementia, electroencephalography, 55:141
multi-infarct dementia, regional cerebral blood flow, 55:141
naltrexone, buprenorphine, 55:181
naltrexone, cingulate gyrus, 55:181
naltrexone, regional cerebral blood flow, 55:181
naltrexone, substance dependence, 55:181
neuroleptic response, basal ganglia, 55:111
neuroleptic response, dopamine receptor, 55:111
neuroleptic response, frontal lobe, 55:111
neuroleptic response, iodobenzamide, 55:111
neuroleptic response, schizophrenia, 55:111
regional cerebral blood flow, Alzheimer's disease, 55:141
regional cerebral blood flow, buprenorphine, 55:181
regional cerebral blood flow, cingulate gyrus, 55:181
regional cerebral blood flow, electroencephalography, 55:141
regional cerebral blood flow, multi-infarct dementia, 55:141
regional cerebral blood flow, naltrexone, 55:181
regional cerebral blood flow, substance dependence, 55:181
schizophrenia, aging, 55:121
schizophrenia, basal ganglia, 55:111
schizophrenia, dopamine receptor, 55:111
schizophrenia, frontal lobe, 55:111, 55:121, 55:131
schizophrenia, iodobenzamide, 55:111
schizophrenia, neuroleptic response, 55:111
schizophrenia, temporal lobe, 55:121
schizophrenia, Wisconsin Card Sort Test, 55:131
sleep deprivation, affective disorder, 55:101
sleep deprivation, cingulate gyrus, 55:101
sleep deprivation, frontal lobe, 55:101
sleep deprivation, hippocampus, 55:101

Single photon emission computed tomography continued
sleep deprivation, melancholia, 55:101
substance dependence, buprenorphine, 55:181
substance dependence, cingulate gyrus, 55:181
substance dependence, naltrexone, 55:181
substance dependence, regional cerebral blood flow, 55:181
temporal lobe, aging, 55:121
temporal lobe, frontal lobe, 55:121
temporal lobe, schizophrenia, 55:121
Tourette's syndrome, basal ganglia, 55:193
Tourette's syndrome, dopamine receptor, 55:193
Tourette's syndrome, iodobenzamide, 55:193
Tourette's syndrome, motor tics, 55:193
Wisconsin Card Sort Test, frontal lobe, 55:131
Wisconsin Card Sort Test, schizophrenia, 55:131
Sleep deprivation
affective disorder, cingulate gyrus, 55:101
affective disorder, frontal lobe, 55:101
affective disorder, hippocampus, 55:101
affective disorder, melancholia, 55:101
affective disorder, single photon emission computed tomography, 55:101
cingulate gyrus, affective disorder, 55:101
cingulate gyrus, melancholia, 55:101
cingulate gyrus, single photon emission computed tomography, 55:101
frontal lobe, affective disorder, 55:101
frontal lobe, melancholia, 55:101
frontal lobe, single photon emission computed tomography, 55:101
hippocampus, affective disorder, 55:101
hippocampus, single photon emission computed tomography, 55:101
melancholia, cingulate gyrus, 55:101
melancholia, frontal lobe, 55:101
melancholia, single photon emission computed tomography, 55:101
single photon emission computed tomography, affective disorder, 55:101
single photon emission computed tomography, cingulate gyrus, 55:101
single photon emission computed tomography, frontal lobe, 55:101
single photon emission computed tomography, hippocampus, 55:101
single photon emission computed tomography, melancholia, 55:101
Substance abuse/dependence
buprenorphine, cingulate gyrus, 55:181
buprenorphine, naltrexone, 55:181
buprenorphine, regional cerebral blood flow, 55:181
buprenorphine, single photon emission computed tomography, 55:181
cingulate gyrus, buprenorphine, 55:181
cingulate gyrus, naltrexone, 55:181
cingulate gyrus, regional cerebral blood flow, 55:181
Substance abuse/dependence
cingulate gyrus, single photon emission computed tomography, 55:181
naltrexone, buprenorphine, 55:181
naltrexone, cingulate gyrus, 55:181
naltrexone, regional cerebral blood flow, 55:181
naltrexone, single photon emission computed tomography, 55:181
regional cerebral blood flow, buprenorphine, 55:181
regional cerebral blood flow, cingulate gyrus, 55:181
regional cerebral blood flow, naltrexone, 55:181
single photon emission computed tomography, buprenorphine, 55:181
single photon emission computed tomography, cingulate gyrus, 55:181
single photon emission computed tomography, naltrexone, 55:181
Temporal lobe
aging, frontal lobe, 55:121
aging, schizophrenia, 55:121
aging, single photon emission computed tomography, 55:121
borderline personality disorder, epilepsy, 55:237
borderline personality disorder, positron emission tomography, 55:237
epilepsy, borderline personality disorder, 55:237
epilepsy, positron emission tomography, 55:237
frontal lobe, aging, 55:121
frontal lobe, schizophrenia, 55:121
frontal lobe, single photon emission computed tomography, 55:121
positron emission tomography, borderline personality disorder, 55: 237
positron emission tomography, epilepsy, 55:237
schizophrenia, aging, 55:121
schizophrenia, frontal lobe, 55:121
schizophrenia, single photon emission computed tomography, 55:121
single photon emission computed tomography, aging, 55:121
single photon emission computed tomography, frontal lobe, 55:121
single photon emission computed tomography, schizophrenia, 55:121
Topographic mapping of brain electrical activity
event related potentials, laterality, 55:153
event related potentials, P300, 55:153
event related potentials, schizophrenia, 55:153
laterality, event related potentials, 55:153
laterality, P300, 55:153
laterality, schizophrenia, 55:153
P300, event related potentials, 55:153
P300, laterality, 55:153
P300, schizophrenia, 55:153
schizophrenia, event related potentials, 55:153
schizophrenia, laterality, 55:153
schizophrenia, P300, 55:153

Tourette's syndrome
amygdala, frontal lobe white matter, 55:205
amygdala, laterality, 55:205
amygdala, magnetic resonance imaging, 55:205
amygdala, T2 relaxation, 55:205
basal ganglia, dopaminereceptor, 55:193
basal ganglia, iodobenzamide, 55:193
basal ganglia, laterality, 55:85
basal ganglia, magnetic resonance imaging, 55:85
basal ganglia, motor tics, 55:85, 55:193
basal ganglia, single photon emission computed tomography, 55:193
corpus callosum, laterality, 55:85
corpus callosum, magnetic resonance imaging, 55:85
corpus callosum, motor tics, 55:85
dopamine receptors, basal ganglia, 55:193
dopamine receptors, iodobenzamide, 55:193
dopamine receptors, motor tics, 55:193
dopamine receptors, single photon emission computed tomography, 55:193
frontal lobe white matter, amygdala, 55:205
frontal lobe white matter, laterality, 55:205
frontal lobe white matter, laterality, 55:205
frontal lobe white matter, magnetic resonance imaging, 55:205
frontal lobe white matter, T2 relaxation, 55:205
iodobenzamide, basal ganglia, 55:193
iodobenzamide, dopamine receptor, 55:193
iodobenzamide, motor tics, 55:193
iodobenzamide, single photon emission computed tomography, 55:193
laterality, amygdala, 55:205
laterality, basal ganglia, 55:85
laterality, corpus callosum, 55:85
laterality, frontal lobe white matter, 55:205
laterality, magnetic resonance imaging, 55:85, 55:205
laterality, motor tics, 55:85
laterality, T2 relaxation, 55:205
magnetic resonance imaging, amygdala, 55:205
magnetic resonance imaging, basal ganglia, 55:85
magnetic resonance imaging, corpus callosum, 55:85
magnetic resonance imaging, frontal lobe white matter, 55:205
magnetic resonance imaging, laterality, 55:85, 55:205
magnetic resonance imaging, motor tics, 55:85
magnetic resonance imaging, T2 relaxation, 55:205
motor tics, basal ganglia, 55:85, 55:193
motor tics, corpus callosum, 55:85
motor tics, dopamine receptor, 55:193
motor tics, iodobenzamide, 55:193
motor tics, laterality, 55:85
motor tics, magnetic resonance imaging, 55:85
motor tics, single photon emission computed tomography, 55:193
single photon emission computed tomography, basal ganglia, 55:193
single photon emission computed tomography, dopamine receptor, 55:193
single photon emission computed tomography, iodobenzamide, 55:193
single photon emission computed tomography, motor tics, 55:193

Tourette's syndrome continued
T2 relaxation, amygdala, 55:205
T2 relaxation, frontal lobe white matter, 55:205
T2 relaxation, laterality, 55:205
T2 relaxation, magnetic resonance imaging, 55:205
Ultrasound, transcranial technique
affective disorder, brainstem, 55:75
affective disorder, dorsal raphe, 55:75
brainstem, affective disorder, 55:75
brainstem, dorsal raphe, 55:75
dorsal raphe, affective disorder, 55:75
dorsal raphe, brainstem, 55:75
Ventricle-brain ratio
affective disorder, bipolar subtype, 55:41
circannual rhythm, computed tomography, 55:65
circannual rhythm, schizophrenia, 55:65
circannual rhythm, season of birth, 55:65
computed tomography, circannual rhythm, 55:65
computed tomography, schizophrenia, 55:65
computed tomography, season of birth, 55:65
magnetic resonance imaging, bipolar affective disorder, 55:41
schizophrenia, circannual rhythm, 55:65
schizophrenia, computed tomography, 55:65
schizophrenia, season of birth, 55:65
season of birth, circannual rhythm, 55:65
season of birth, computed tomography, 55:65
season of birth, schizophrenia, 55:65
Wisconsin Card Sorting Test
frontal lobe, regional cerebral blood flow, 55:51
frontal lobe, schizophrenia, 55:51, 55:131
frontal lobe, single photon emission computed tomography, 55:131
frontal lobe, twins, 55:51
genetics, schizophrenia, 55:51
neuropsychology, frontal lobe, 55:51
neuropsychology, schizophrenia, 55:51
neuropsychology, twins, 55:51
regional cerebral blood flow, frontal lobe, 55:51
regional cerebral blood flow, hippocampus, 55:51
regional cerebral blood flow, neuropsychology, 55:51
regional cerebral blood flow, schizophrenia, 55:51
regional cerebral blood flow, twins, 55:51
schizophrenia, frontal lobe, 55:51, 55:131
schizophrenia, genetics, 55:51
schizophrenia, hippocampus, 55:51
schizophrenia, neuropsychology, 55:51
schizophrenia, regional cerebral blood flow, 55:51
schizophrenia, single photon emission computed tomography, 55:131
schizophrenia, twins, 55:51
single photon emission computed tomography, frontal lobe, 55:131
single photon emission computed tomography, schizophrenia, 55:131
twins, frontal lobe, 55:51
twins, genetics, 55:51
twins, hippocampus, 55:51
twins, neuropsychology, 55:51
twins, regional cerebral blood flow, 55:51
twins, schizophrenia, 55:51